Odyssey Therapeutics Prices 15.5M Shares at $18.00
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 08 2026
0mins
Odyssey Therapeutics priced 15.5M shares at $18.00. The deal size was increased to 15.5M shares from 13.2M and priced at the top end of the $16.00-$18.00 range. JPMorgan, TD Securities, Cantor Fitzgerald, Wedbush and Oppenheimer are acting as joint book running managers for the offering. Odyssey is a clinical-stage biopharmaceutical company that says it is "seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ODTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ODTX
Wall Street analysts forecast ODTX stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 16.960
Low
Averages
High
Current: 16.960
Low
Averages
High
About ODTX
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its advanced programs include OD-001, an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4. These programs have the potential to yield treatments for inflammatory and autoimmune diseases. In addition to its advanced programs, it has a portfolio of preclinical programs that include a regulatory T cell, or Treg, -specific tumor necrosis factor receptor 2, or TNFR2, agonist, a bispecific antagonist of thymic stromal lymphopoietin, or TSLP, and interleukin-33, or IL-33, and an interleukin-1 receptor-associated kinase 4, or IRAK4, scaffolding inhibitor. It also has an interferon regulatory factor 5, or IRF5, inhibitor in preclinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Latest Rating Changes on Wall Street
- TripAdvisor Upgrade: Wedbush upgraded TripAdvisor from neutral to outperform, citing the stock's undervaluation and expected governance transformation post-LTRIP merger, alongside activist involvement as catalysts for future growth.
- Knight-Swift Outlook: Susquehanna upgraded Knight-Swift from neutral to positive, highlighting strong earnings prospects in the trucking sector, although it noted that much of the good news is already priced in.
- Mobia Medical Coverage Initiation: Goldman Sachs initiated coverage on Mobia Medical with a buy rating and a $31 price target, indicating approximately 130% upside potential, reflecting the company's strong growth prospects in the medtech space.
- Intuit Downgrade: Goldman Sachs downgraded Intuit from neutral to sell, expressing concerns over heightened competition and noting a 46% year-to-date decline in stock price, which raises doubts about its future profitability.
See More
Five IPOs and Three SPACs Priced This Week
- HawkEye 360 IPO Performance: HawkEye 360 priced at the top of its range, raising $416 million with a market cap of $2.8 billion; despite being unprofitable, its strong revenue growth and increasing backlog indicate significant potential in the defense technology sector.
- Odyssey Therapeutics Financing: Odyssey Therapeutics priced its upsized IPO at the top of the range, raising $279 million with a market cap of $911 million; although its stock fell 9%, the development of targeted therapies for autoimmune diseases suggests robust market demand.
- Suja Life Market Challenges: Suja Life priced at the bottom of its range, raising $187 million with an $813 million market cap; despite leading in the cold-pressed juice market, a 15% decline in stock price highlights potential threats from shifting consumer preferences.
- Rare Earths Americas IPO Success: Rare Earths Americas priced at the top of its range, raising $63 million with a market cap of $399 million; focusing on heavy rare earth elements, its stock rose 23% during the week, reflecting market confidence in its growth prospects.
See More
Odyssey and Mobia Stocks Plummet After IPOs Raising Over $450M
- Odyssey IPO Performance: Odyssey Therapeutics (ODTX) raised approximately $304 million in its IPO, opening at $20, an 11% increase from its $18 offering price, but by 2 PM ET, the stock had declined to $16.49, reflecting an 8% pullback that raises concerns about its long-term growth potential.
- Mobia Stock Fluctuation: Mobia Medical (MOBI) raised $150 million in its IPO, opening at $14, down 7% from its $15 offering price, and further dropped to $11.49 by 2:10 PM ET, indicating a 23% decline, suggesting a lack of investor confidence in its market outlook.
- Market Reaction Analysis: Both companies experienced significant stock price declines post-IPO, indicating that despite raising over $450 million, the market remains cautious about the short-term performance of the biotech and MedTech sectors, which could impact future fundraising capabilities.
- Investor Confidence Challenge: The IPO performances of Odyssey and Mobia reflect a testing of investor confidence in newly listed companies, particularly in the current economic climate, which may lead to diminished interest in similar firms in the future.
See More
Odyssey Therapeutics Raises $25 Million in Private Placement
- Funding Details: Odyssey Therapeutics successfully raised $25 million through a private placement of 1.39 million shares to an affiliate of TPG Life Sciences Innovations, enhancing its financial capacity to support ongoing research and development.
- Drug Development Plans: The company intends to use the proceeds to advance the development of OD-001, its leading drug candidate for ulcerative colitis and Crohn's disease, while also progressing the SLC15A4 program and other clinical activities.
- IPO Performance: Odyssey Therapeutics debuted on Nasdaq at $20 per share, achieving a valuation of $900 million, although the stock has since fallen to $16 per share, representing a nearly 10% decline from its issue price of $18.
- Financial Status: As of March 31, 2026, the company reported $175.7 million in cash and marketable securities, despite a net loss of $148.6 million in 2025, indicating ongoing financial pressure from its research investments.
See More
Odyssey Therapeutics Prices IPO, Raising Over $300M
- Expanded Financing: Odyssey Therapeutics successfully priced 15.5 million shares at $18 each in its IPO, raising over $300 million, reflecting strong market confidence in its immunology research.
- Underwriter Option: The company granted underwriters a 30-day option to purchase approximately 2.3 million additional shares at the IPO price, a strategy aimed at enhancing market liquidity and attracting more investors.
- Successful Private Placement: Concurrently with the IPO, Odyssey sold about 1.4 million shares of common stock to a unit of TPG Life Sciences Innovations, further solidifying its capital base and ensuring smooth financing.
- Adjusted Financing Goals: Initially planning to offer around 13.2 million shares at $16 to $18 each, expecting nearly $205.2 million in net proceeds, the final financing results significantly exceeded expectations, reflecting investor optimism about the company's future.
See More
Odyssey Therapeutics Raises $279 Million in IPO for Autoimmune Disease Therapies
- Fundraising Success: Odyssey Therapeutics successfully raised $279 million by offering 15.5 million shares at $18 each, reaching the high end of the $16 to $18 range, indicating strong market demand for its precision therapies.
- Investor Confidence: Existing shareholder TPG Life Sciences Innovations invested $25 million at $18 per share in a concurrent private placement, reflecting confidence in Odyssey's future growth and strengthening the company's financial foundation.
- Research Focus: Odyssey is dedicated to developing targeted therapies for autoimmune and inflammatory diseases, with lead programs including oral small-molecule candidates targeting RIPK2 and SLC15A4, which have shown early clinical efficacy in ulcerative colitis, suggesting significant future market potential.
- Market Positioning: Based in Boston, Odyssey will trade on Nasdaq under the symbol ODTX, leveraging its expertise in drug discovery and immunobiology to address the unmet needs in treatment options for conditions like inflammatory bowel disease and lupus.
See More
Latest Rating Changes on Wall Street
- TripAdvisor Upgrade: Wedbush upgraded TripAdvisor from neutral to outperform, citing the stock's undervaluation and expected governance transformation post-LTRIP merger, alongside activist involvement as catalysts for future growth.
- Knight-Swift Outlook: Susquehanna upgraded Knight-Swift from neutral to positive, highlighting strong earnings prospects in the trucking sector, although it noted that much of the good news is already priced in.
- Mobia Medical Coverage Initiation: Goldman Sachs initiated coverage on Mobia Medical with a buy rating and a $31 price target, indicating approximately 130% upside potential, reflecting the company's strong growth prospects in the medtech space.
- Intuit Downgrade: Goldman Sachs downgraded Intuit from neutral to sell, expressing concerns over heightened competition and noting a 46% year-to-date decline in stock price, which raises doubts about its future profitability.
See More
Five IPOs and Three SPACs Priced This Week
- HawkEye 360 IPO Performance: HawkEye 360 priced at the top of its range, raising $416 million with a market cap of $2.8 billion; despite being unprofitable, its strong revenue growth and increasing backlog indicate significant potential in the defense technology sector.
- Odyssey Therapeutics Financing: Odyssey Therapeutics priced its upsized IPO at the top of the range, raising $279 million with a market cap of $911 million; although its stock fell 9%, the development of targeted therapies for autoimmune diseases suggests robust market demand.
- Suja Life Market Challenges: Suja Life priced at the bottom of its range, raising $187 million with an $813 million market cap; despite leading in the cold-pressed juice market, a 15% decline in stock price highlights potential threats from shifting consumer preferences.
- Rare Earths Americas IPO Success: Rare Earths Americas priced at the top of its range, raising $63 million with a market cap of $399 million; focusing on heavy rare earth elements, its stock rose 23% during the week, reflecting market confidence in its growth prospects.
See More
Odyssey and Mobia Stocks Plummet After IPOs Raising Over $450M
- Odyssey IPO Performance: Odyssey Therapeutics (ODTX) raised approximately $304 million in its IPO, opening at $20, an 11% increase from its $18 offering price, but by 2 PM ET, the stock had declined to $16.49, reflecting an 8% pullback that raises concerns about its long-term growth potential.
- Mobia Stock Fluctuation: Mobia Medical (MOBI) raised $150 million in its IPO, opening at $14, down 7% from its $15 offering price, and further dropped to $11.49 by 2:10 PM ET, indicating a 23% decline, suggesting a lack of investor confidence in its market outlook.
- Market Reaction Analysis: Both companies experienced significant stock price declines post-IPO, indicating that despite raising over $450 million, the market remains cautious about the short-term performance of the biotech and MedTech sectors, which could impact future fundraising capabilities.
- Investor Confidence Challenge: The IPO performances of Odyssey and Mobia reflect a testing of investor confidence in newly listed companies, particularly in the current economic climate, which may lead to diminished interest in similar firms in the future.
See More
Odyssey Therapeutics Raises $25 Million in Private Placement
- Funding Details: Odyssey Therapeutics successfully raised $25 million through a private placement of 1.39 million shares to an affiliate of TPG Life Sciences Innovations, enhancing its financial capacity to support ongoing research and development.
- Drug Development Plans: The company intends to use the proceeds to advance the development of OD-001, its leading drug candidate for ulcerative colitis and Crohn's disease, while also progressing the SLC15A4 program and other clinical activities.
- IPO Performance: Odyssey Therapeutics debuted on Nasdaq at $20 per share, achieving a valuation of $900 million, although the stock has since fallen to $16 per share, representing a nearly 10% decline from its issue price of $18.
- Financial Status: As of March 31, 2026, the company reported $175.7 million in cash and marketable securities, despite a net loss of $148.6 million in 2025, indicating ongoing financial pressure from its research investments.
See More
Odyssey Therapeutics Prices IPO, Raising Over $300M
- Expanded Financing: Odyssey Therapeutics successfully priced 15.5 million shares at $18 each in its IPO, raising over $300 million, reflecting strong market confidence in its immunology research.
- Underwriter Option: The company granted underwriters a 30-day option to purchase approximately 2.3 million additional shares at the IPO price, a strategy aimed at enhancing market liquidity and attracting more investors.
- Successful Private Placement: Concurrently with the IPO, Odyssey sold about 1.4 million shares of common stock to a unit of TPG Life Sciences Innovations, further solidifying its capital base and ensuring smooth financing.
- Adjusted Financing Goals: Initially planning to offer around 13.2 million shares at $16 to $18 each, expecting nearly $205.2 million in net proceeds, the final financing results significantly exceeded expectations, reflecting investor optimism about the company's future.
See More
Odyssey Therapeutics Raises $279 Million in IPO for Autoimmune Disease Therapies
- Fundraising Success: Odyssey Therapeutics successfully raised $279 million by offering 15.5 million shares at $18 each, reaching the high end of the $16 to $18 range, indicating strong market demand for its precision therapies.
- Investor Confidence: Existing shareholder TPG Life Sciences Innovations invested $25 million at $18 per share in a concurrent private placement, reflecting confidence in Odyssey's future growth and strengthening the company's financial foundation.
- Research Focus: Odyssey is dedicated to developing targeted therapies for autoimmune and inflammatory diseases, with lead programs including oral small-molecule candidates targeting RIPK2 and SLC15A4, which have shown early clinical efficacy in ulcerative colitis, suggesting significant future market potential.
- Market Positioning: Based in Boston, Odyssey will trade on Nasdaq under the symbol ODTX, leveraging its expertise in drug discovery and immunobiology to address the unmet needs in treatment options for conditions like inflammatory bowel disease and lupus.
See More
